{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:38:23Z","timestamp":1787027903478,"version":"build-2736575974"},"reference-count":49,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin International"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Patients with advanced-stage mycosis fungoides (MF IIB\u2013IVB) and S\u00e9zary syndrome (SS) have poor prognoses, with survival ranging from 4.7 to 1.4 years depending on the disease stage. There is a need for therapeutic approaches that lead to long-lasting responses and improved quality of life and survival. Mogamulizumab, a humanized antibody against the CCR4 molecule, and low-dose total skin electron beam therapy (TSEBT) are two known established treatments for MF and SS as a monotherapy. However, little is known about the potential additive effect on the combination of both treatments. We report here for the first time the concurrent use of low-dose hypofractionated TSEBT (2 \u00d7 4 Gy) with mogamulizumab. Based on two relapsed\/refractory and advanced-stage CTCL patients, we show that this combination may be well tolerated in advanced-stage MF or SS and may potentially lead to an additive treatment effect on response times, particularly in the skin and blood within two weeks. We propose that this combination may be a treatment option for patients with SS. Further research is needed to understand the efficacy and tolerability profile of this therapeutic combination and to determine if there is an additive effect of the combination on the response rates when compared with the monotherapy.<\/jats:p>","DOI":"10.3390\/curroncol31090400","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T04:25:22Z","timestamp":1726201522000},"page":"5412-5421","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Mogamulizumab and Concomitant Hypofractionated Low-Dose Total Skin Electron Beam Therapy (2 \u00d7 4 Gy) in Cutaneous T-Cell Lymphoma: Proof of Principle, Report of Two Cases"],"prefix":"10.3390","volume":"31","author":[{"given":"Mathias","family":"Oymanns","sequence":"first","affiliation":[{"name":"Department of Dermatology, Helios Hospital Krefeld, 47805 Krefeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Daum-Marzian","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Helios Hospital Krefeld, 47805 Krefeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7898-9432","authenticated-orcid":false,"given":"Chalid","family":"Assaf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Helios Hospital Krefeld, 47805 Krefeld, Germany"},{"name":"Institute for Molecular Medicine, Medical School Hamburg, 20457 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-021-00296-9","article-title":"Cutaneous T cell lymphoma","volume":"7","author":"Dummer","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1610-0387.2007.06337.x","article-title":"Cutaneous lymphomas in Germany: An analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG)","volume":"5","author":"Assaf","year":"2007","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_3","first-page":"537","article-title":"S2k-Guidelines\u2014Cutaneous lymphomas (ICD10 C82-C86): Update 2021","volume":"20","author":"Dippel","year":"2022","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/ajd.12349","article-title":"Mycosis fungoides and Sezary syndrome: Current challenges in assessment, management and prognostic markers","volume":"57","author":"Hughes","year":"2016","journal-title":"Australas. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: Validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome\u2014Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/ajh.26299","article-title":"Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management","volume":"96","author":"Hristov","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_9","unstructured":"European Medicines Agency (2024, January 02). POTELIGEO (Mogamulizumab) Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/poteligeo-epar-product-information_en.pdf."},{"key":"ref_10","unstructured":"US Food and Drug Administration (2024, January 02). POTELIGEO (Mogamulizumab) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761051s000lbl.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e15634","DOI":"10.1111\/dth.15634","article-title":"Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma","volume":"35","author":"Bagot","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): An international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/jdv.18549","article-title":"Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sezary syndrome","volume":"37","author":"Booken","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/jdv.19134","article-title":"Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sezary syndrome: A multicentre, retrospective, real-world French study","volume":"37","author":"Quereux","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjd.20708","article-title":"Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: A retrospective single-centre case series","volume":"186","author":"Trum","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.2021013341","article-title":"Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients","volume":"139","author":"Darbord","year":"2022","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/jdv.19801","article-title":"Clinicopathological definition, management and prognostic value of mogamulizumab-associated rash and other cutaneous events: A systematic review","volume":"38","author":"Avallone","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-021-00624-7","article-title":"Dermatologic events associated with the anti-CCR4 antibody mogamulizumab: Characterization and management","volume":"12","author":"Musiek","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamadermatol.2019.0369","article-title":"Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides but Possibly Indicating Durable Clinical Response","volume":"155","author":"Chen","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_20","first-page":"1079","article-title":"Mogamulizumab-associated rash\u2013Case series and review of the literature","volume":"22","author":"Hansen","year":"2024","journal-title":"J. Der Dtsch. Dermatol. Ges."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0360-3016(77)90182-1","article-title":"The rationale for curative radiotherapy in mycosis fungoides","volume":"2","author":"Hoppe","year":"1977","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"113343","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014Update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: Field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1067\/mjd.2000.105510","article-title":"Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides","volume":"43","author":"Wilson","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamadermatol.2020.3958","article-title":"Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of S\u00e9zary Syndrome: Clinical, Immunologic, and Molecular Analysis","volume":"157","author":"Durgin","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_26","first-page":"279","article-title":"Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphoma","volume":"20","author":"Elsayad","year":"2022","journal-title":"J. Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","article-title":"Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: Updated results from a single institution","volume":"26","author":"Hosing","year":"2015","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jaad.2012.09.056","article-title":"Improvement in peripheral blood disease burden in patients with Sezary syndrome and leukemic mycosis fungoides after total skin electron beam therapy","volume":"68","author":"Klein","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gorica, J., De Feo, M.S., Corica, F., Sidrak, M.M.A., Conte, M., Filippi, L., Schillaci, O., De Vincentis, G., and Frantellizzi, V. (2023). Novel Theranostic Approaches Targeting CCR4-Receptor, Current Status and Translational Prospectives: A Systematic Review. Pharmaceuticals, 16.","DOI":"10.3390\/ph16020313"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"113521","DOI":"10.1016\/j.ejca.2023.113521","article-title":"CC chemokine receptor 4 (CCR4)-positive regulatory T cells interact with tumor-associated macrophages to facilitate metastatic potential after radiation","volume":"198","author":"Chiang","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaad.2014.10.014","article-title":"Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials","volume":"72","author":"Hoppe","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijrobp.2015.01.047","article-title":"Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: An open clinical study and pooled data analysis","volume":"92","author":"Kamstrup","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ijrobp.2017.05.052","article-title":"The results of Low dose Total Skin Electron Beam Radiotherapy (TSEB), in patients with mycosis fungoides from the UK cutaneous lymphoma group","volume":"99","author":"Morris","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2015.08.041","article-title":"Total skin electron beam for primary cutaneous T-cell lymphoma","volume":"93","author":"Elsayad","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jaad.2020.11.058","article-title":"Ultra-hypofractionated low-dose total skin electron beam followed by maintenance therapy: Preliminary findings from a prospective open-label study","volume":"85","author":"Rolf","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/j.prro.2022.10.004","article-title":"Optimizing Palliative Focal Radiation Therapy Dose in Cutaneous T-Cell Lymphoma: How Low Can You Go?","volume":"13","author":"Patel","year":"2023","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.prro.2023.03.015","article-title":"Single-Fraction Radiation Therapy for Localized Cutaneous T-Cell Lymphoma","volume":"13","author":"Wang","year":"2023","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"109430","DOI":"10.1016\/j.radonc.2022.11.019","article-title":"Excellent treatment outcomes from low dose radiation therapy for primary cutaneous CD4+ small\/medium T-Cell lymphoproliferative disorder","volume":"178","author":"Ward","year":"2023","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_40","first-page":"38","article-title":"The CARE guidelines: Consensus-based clinical case reporting guideline development","volume":"2","author":"Gagnier","year":"2013","journal-title":"BMJ Case Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijrobp.2023.02.052","article-title":"Ultra-hypofractionated low-dose total skin electron beam in advanced stage mycosis fungoides and S\u00e9zary syndrome","volume":"117","author":"Elsayad","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_42","unstructured":"Bojanini, L., Herrera, M., Li, S., Xu, N., Ahmed, A.A., Khodadoust, M., and Kim, Y.H. (2023, January 13\u201317). Long-term outcomes with mogamulizumab alone or in combination with other therapies for the treatment of cutaneous T-cell lymphoma. Proceedings of the 17th International Conference on Malignant Lymphoma, Lugano, Switzerland."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.clml.2014.09.013","article-title":"Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients with Sezary Syndrome","volume":"15","author":"Polansky","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"100629","DOI":"10.1016\/j.adro.2020.11.014","article-title":"Low-dose total skin electron beam therapy combined with mogamulizumab for refractory mycosis fungoides and S\u00e9zary syndrome","volume":"6","author":"Fong","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/0008-5472.CAN-14-1931","article-title":"Tumor radiosensitization by monomethyl auristatin E: Mechanism of action and targeted delivery","volume":"75","author":"Buckel","year":"2015","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/bjd\/ljac012","article-title":"Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma","volume":"188","author":"Oymanns","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0959-8049(22)00595-0","article-title":"Concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam therapy in 14 patients with tumor stage mycosis fungoides or S\u00e9zary syndrome","volume":"173","author":"Oymanns","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_48","unstructured":"European Organisation for Research and Treatment of Cancer (2024, September 02). Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients with Stage IB-IIB Cutaneous T-Cell Lymphoma, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04128072."},{"key":"ref_49","unstructured":"(2024, September 02). Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & S\u00e9zary Syndrome, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04256018."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/400\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:55:18Z","timestamp":1760111718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["curroncol31090400"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31090400","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]}}}